Clinical-stage Opportunity Biopharma partnerships for late-stage development and potential commercialization of NA-831 and NA-704, leveraging NeuroActiva's Phase 2A proof of safety and efficacy to accelerate Phase 2B/3 timelines.

Oral and IV Modalities NA-831 is oral, while NA-704 is intravenous weekly, suggesting cross-portfolio collaboration with contract manufacturing, specialty pharmacies, and infusion center networks to support diverse administration routes.

Delivery Innovation MICROS Controlled Release Infusion System enables hospital and home infusion delivery, presenting co-marketing and device integration opportunities with infusion service providers and hospital systems.

Specialized Market Fit Focused on Alzheimer's disease with a platform targeting neuroprotection and neurogenesis; potential for expansion into other neurological disorders through partnerships with academic medical centers and biotech companies pursuing CNS targets.

Growth Readiness Small team scale and subsidiary structure under Biomed Industries indicate a strategic need for outsourcing, CRO/CMO partnerships, and early-stage investment collaborations to scale operations and clinical execution.